1. Home
  2. ENIC vs PTGX Comparison

ENIC vs PTGX Comparison

Compare ENIC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ENIC

Enel Chile S.A. (Each representing 50 shares of)

HOLD

Current Price

$4.41

Market Cap

6.2B

Sector

Utilities

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$120.43

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENIC
PTGX
Founded
2016
2006
Country
Chile
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.4B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
ENIC
PTGX
Price
$4.41
$120.43
Analyst Decision
Hold
Strong Buy
Analyst Count
1
13
Target Price
N/A
$108.23
AVG Volume (30 Days)
586.3K
705.9K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
4.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
N/A
Revenue This Year
$96,491.22
$874.25
Revenue Next Year
$2.63
N/A
P/E Ratio
$101.18
$2,455.60
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$49.86
52 Week High
$4.74
$126.25

Technical Indicators

Market Signals
Indicator
ENIC
PTGX
Relative Strength Index (RSI) 50.70 66.64
Support Level $4.33 $94.48
Resistance Level $4.73 N/A
Average True Range (ATR) 0.12 4.67
MACD -0.00 1.54
Stochastic Oscillator 54.14 77.87

Price Performance

Historical Comparison
ENIC
PTGX

About ENIC Enel Chile S.A. (Each representing 50 shares of)

Enel Chile SA is an electricity utility company engaged, through its subsidiaries and affiliates, in the generation, transmission, and distribution of electricity across Chile. The Company operates through two main segments: the Generation Business, which includes companies that own and operate power plants supplying electricity to the grid and generates the majority of revenue; and the Distribution and Network Business, which consists of companies operating under public utility concessions to distribute electricity to end customers.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: